Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinants of response to hydroxyurea (HU)

M. H. Steinbarg, Z. H. Lu, F. Barton, M. Terrin, S. Charache, George J Dover

Research output: Contribution to journalArticle

Abstract

HU can increase Hb F in HbSS and temper the course of disease. In a trial of HU in 295 adult HbSS patients, we studied genetic elements that could mark regions that regulate γ-globin gene expression (X-linked F-cell production (FCP) locus and β-globin gene haplotype), and other factors that might predict the response to HU. Patients were treated for a mean of 28 months (range 21-36) and HU dose escalated according to the blood cell counts. At baseline, Hb F levels and associated measurements were higher in females than in males. Highest baseline Hb F measures were associated with the high FCP allele. Hb F rose from 5.1% at baseline to 8.4% in patients assigned to HU - 9.7% in females, 7.0% in males - and was not appreciably changed in patients given placebo. We classified the Hb F response to HU into 4 groups; very high (8% of 150 patients), high (30%), moderate (37%) and low (26%). Baseline Hb F was about 5% in all 4 groups. Hb F increased to 19% in the very high and to 13% in the high group, but was nearly unchanged in other two. Benin haplotype homozygosity, the capacity to be titrated to toxic doses of HU and an HU dose of 15-22.5 mg/kg contributed to the response, but gender and FCP locus did not. Responses of Hb F to HU were strongly related to the baseline measurements and were blunted by the Bantu haplotype. Bone marrow activity, estimated by baseline reticulocyte and leukocyte counts, was a key element in the Hb F response. Patients with the most active bone marrows, that is, the highest leukocyte and reticulocyte counts, had the greatest decrements in these counts, required only modest doses of HU and had the most sizable increments of Hb F. In 26% of our patients, insufficient "bone marrow reserve" precluded achieving a safe marrow-suppressive dose of HU and as a result, no Hb F response occurred. However, about 40% of these severely affected HbSS patients had Hb F responses to HU that are likely to be clinically important. "Bone marrow reserve" is a major predictor of the Hb F response to HU.

Original languageEnglish (US)
JournalJournal of Investigative Medicine
Volume44
Issue number1
StatePublished - 1996
Externally publishedYes

Fingerprint

Fetal Hemoglobin
Hydroxyurea
Sickle Cell Anemia
Bone Marrow
Bone
Haplotypes
Reticulocyte Count
Globins
Leukocyte Count
Benin
Blood Cell Count
Poisons
Gene expression

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS) : Determinants of response to hydroxyurea (HU). / Steinbarg, M. H.; Lu, Z. H.; Barton, F.; Terrin, M.; Charache, S.; Dover, George J.

In: Journal of Investigative Medicine, Vol. 44, No. 1, 1996.

Research output: Contribution to journalArticle

Steinbarg, M. H. ; Lu, Z. H. ; Barton, F. ; Terrin, M. ; Charache, S. ; Dover, George J. / Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS) : Determinants of response to hydroxyurea (HU). In: Journal of Investigative Medicine. 1996 ; Vol. 44, No. 1.
@article{ac584dc7ebd04defaab8de8a44e06d47,
title = "Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinants of response to hydroxyurea (HU)",
abstract = "HU can increase Hb F in HbSS and temper the course of disease. In a trial of HU in 295 adult HbSS patients, we studied genetic elements that could mark regions that regulate γ-globin gene expression (X-linked F-cell production (FCP) locus and β-globin gene haplotype), and other factors that might predict the response to HU. Patients were treated for a mean of 28 months (range 21-36) and HU dose escalated according to the blood cell counts. At baseline, Hb F levels and associated measurements were higher in females than in males. Highest baseline Hb F measures were associated with the high FCP allele. Hb F rose from 5.1{\%} at baseline to 8.4{\%} in patients assigned to HU - 9.7{\%} in females, 7.0{\%} in males - and was not appreciably changed in patients given placebo. We classified the Hb F response to HU into 4 groups; very high (8{\%} of 150 patients), high (30{\%}), moderate (37{\%}) and low (26{\%}). Baseline Hb F was about 5{\%} in all 4 groups. Hb F increased to 19{\%} in the very high and to 13{\%} in the high group, but was nearly unchanged in other two. Benin haplotype homozygosity, the capacity to be titrated to toxic doses of HU and an HU dose of 15-22.5 mg/kg contributed to the response, but gender and FCP locus did not. Responses of Hb F to HU were strongly related to the baseline measurements and were blunted by the Bantu haplotype. Bone marrow activity, estimated by baseline reticulocyte and leukocyte counts, was a key element in the Hb F response. Patients with the most active bone marrows, that is, the highest leukocyte and reticulocyte counts, had the greatest decrements in these counts, required only modest doses of HU and had the most sizable increments of Hb F. In 26{\%} of our patients, insufficient {"}bone marrow reserve{"} precluded achieving a safe marrow-suppressive dose of HU and as a result, no Hb F response occurred. However, about 40{\%} of these severely affected HbSS patients had Hb F responses to HU that are likely to be clinically important. {"}Bone marrow reserve{"} is a major predictor of the Hb F response to HU.",
author = "Steinbarg, {M. H.} and Lu, {Z. H.} and F. Barton and M. Terrin and S. Charache and Dover, {George J}",
year = "1996",
language = "English (US)",
volume = "44",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS)

T2 - Determinants of response to hydroxyurea (HU)

AU - Steinbarg, M. H.

AU - Lu, Z. H.

AU - Barton, F.

AU - Terrin, M.

AU - Charache, S.

AU - Dover, George J

PY - 1996

Y1 - 1996

N2 - HU can increase Hb F in HbSS and temper the course of disease. In a trial of HU in 295 adult HbSS patients, we studied genetic elements that could mark regions that regulate γ-globin gene expression (X-linked F-cell production (FCP) locus and β-globin gene haplotype), and other factors that might predict the response to HU. Patients were treated for a mean of 28 months (range 21-36) and HU dose escalated according to the blood cell counts. At baseline, Hb F levels and associated measurements were higher in females than in males. Highest baseline Hb F measures were associated with the high FCP allele. Hb F rose from 5.1% at baseline to 8.4% in patients assigned to HU - 9.7% in females, 7.0% in males - and was not appreciably changed in patients given placebo. We classified the Hb F response to HU into 4 groups; very high (8% of 150 patients), high (30%), moderate (37%) and low (26%). Baseline Hb F was about 5% in all 4 groups. Hb F increased to 19% in the very high and to 13% in the high group, but was nearly unchanged in other two. Benin haplotype homozygosity, the capacity to be titrated to toxic doses of HU and an HU dose of 15-22.5 mg/kg contributed to the response, but gender and FCP locus did not. Responses of Hb F to HU were strongly related to the baseline measurements and were blunted by the Bantu haplotype. Bone marrow activity, estimated by baseline reticulocyte and leukocyte counts, was a key element in the Hb F response. Patients with the most active bone marrows, that is, the highest leukocyte and reticulocyte counts, had the greatest decrements in these counts, required only modest doses of HU and had the most sizable increments of Hb F. In 26% of our patients, insufficient "bone marrow reserve" precluded achieving a safe marrow-suppressive dose of HU and as a result, no Hb F response occurred. However, about 40% of these severely affected HbSS patients had Hb F responses to HU that are likely to be clinically important. "Bone marrow reserve" is a major predictor of the Hb F response to HU.

AB - HU can increase Hb F in HbSS and temper the course of disease. In a trial of HU in 295 adult HbSS patients, we studied genetic elements that could mark regions that regulate γ-globin gene expression (X-linked F-cell production (FCP) locus and β-globin gene haplotype), and other factors that might predict the response to HU. Patients were treated for a mean of 28 months (range 21-36) and HU dose escalated according to the blood cell counts. At baseline, Hb F levels and associated measurements were higher in females than in males. Highest baseline Hb F measures were associated with the high FCP allele. Hb F rose from 5.1% at baseline to 8.4% in patients assigned to HU - 9.7% in females, 7.0% in males - and was not appreciably changed in patients given placebo. We classified the Hb F response to HU into 4 groups; very high (8% of 150 patients), high (30%), moderate (37%) and low (26%). Baseline Hb F was about 5% in all 4 groups. Hb F increased to 19% in the very high and to 13% in the high group, but was nearly unchanged in other two. Benin haplotype homozygosity, the capacity to be titrated to toxic doses of HU and an HU dose of 15-22.5 mg/kg contributed to the response, but gender and FCP locus did not. Responses of Hb F to HU were strongly related to the baseline measurements and were blunted by the Bantu haplotype. Bone marrow activity, estimated by baseline reticulocyte and leukocyte counts, was a key element in the Hb F response. Patients with the most active bone marrows, that is, the highest leukocyte and reticulocyte counts, had the greatest decrements in these counts, required only modest doses of HU and had the most sizable increments of Hb F. In 26% of our patients, insufficient "bone marrow reserve" precluded achieving a safe marrow-suppressive dose of HU and as a result, no Hb F response occurred. However, about 40% of these severely affected HbSS patients had Hb F responses to HU that are likely to be clinically important. "Bone marrow reserve" is a major predictor of the Hb F response to HU.

UR - http://www.scopus.com/inward/record.url?scp=33749543726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749543726&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749543726

VL - 44

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 1

ER -